Research programme: antibody-drug nanocell conjugates - EnGeneICAlternative Names: EGFR VEDVsPNU
Latest Information Update: 16 Jan 2017
At a glance
- Originator EnGeneIC
- Class Drug conjugates; Immunoconjugates
- Mechanism of Action DNA repair inhibitors; DNA topoisomerase I inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 10 Jan 2017 EngeneIC plans a phase I trial for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in Australia (ACTRN12617000037303p)
- 20 May 2016 Preclinical trials in Cancer in Australia (IV)